Spinal Cord Injury Neurorecovery Collaboration

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Melbourne

About this trial

SCINC is an adaptive design Master protocol that seeks to determine if there is "sufficient promise" of beneficial effect of treatment combinations to enhance motor recovery in pre-specified strata of people with a spinal cord injury.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Adults > 18 years of age

Able to independently ventilate

Chronic SCI (>1 years post-injury or impairment onset)

Tetraplegia (C2-T1 level of injury)

Trial design

Design model

Single group

Treatments tested in this trial

  • Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)

    Other intervention

    TIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.

Treatment groups

24 Participants
are divided into 1 treatment group
Group A: RRULI: Appendix 1Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

At an individual participant level, the Phase IIA study has a single, binary, composite primary outcome to determine if there is a 'signal of benefit', measuring effectiveness, no deterioration, safety and acceptability.

The single binary outcome includes the following components: A) Effectiveness - Increase above baseline that is equal or more than the predefined outcome-specific stated thresholds, on at least ONE of the: Action Reach Arm Test (ARAT), Handheld dynamometer (GRIP) Maximal inspiratory pressure (MIP) B) No deterioration - No deterioration below baseline. C) Safety - Incidence of Autonomic Dysreflexia (AD) episodes occurring during the intervention period for each individual participant. D) Acceptability - Rate of participant adherence to intervention sessions. Please refer to the following primary outcomes for details of each of these components.

Time frame
Baseline and 6-weeks.
2

A) Effectiveness: Increase above baseline that is equal or more than the predefined outcome-specific stated thresholds, on at least ONE of the: Action Reach Arm Test (ARAT), Handheld dynamometer (GRIP) Maximal inspiratory pressure (MIP)

ARAT: Assesses grasp, grip, pinch and gross movement. A minimal clinically important difference of 5.7 points is accepted in SCI. GRIP: Grip strength will be measured according to a standardised procedure. A threshold of 5.0 kg will be used. MIP: Respiratory muscle strength will be measured according to standard procedures. A threshold of 10cmH20 will be used.

Time frame
Baseline and 6 week follow-up
3

B) No deterioration

No deterioration (decline below baseline) that is equal or more than the predefined outcome-specific stated threshold, on ANY of the ARAT, GRIP and MIP.

Time frame
Baseline and 6 week follow-up
4

C) Safety - Incidence of Autonomic Dysreflexia (AD) episodes occurring during the intervention period for each individual participant.

Fewer than two AD events that fail to resolve with participants usual, community interventions.

Time frame
Up to 6 weeks.

Secondary outcomes

1

9-hole Peg test

A test of upper limb dexterity and function. This test will be undertaken using the dominant hand.

Time frame
Baseline and 6-weeks.
2

Pinch grip dynamometer

Pinch strength

Time frame
Baseline and 6-weeks.
3

Penn Spasm Frequency Scale

Self-report measure of upper limb spasticity composed of 2-parts: 1. Spasm frequency: scale 0 (no spasm) - 4 (spasms occurring more than 10 times per hour). 2. Spasm severity: scale 1 (mild) - 3 (severe). A higher score indicates a worse outcome for both components of the scale.

Time frame
Baseline and 6-weeks.
4

Capabilities of upper extremity questionnaire

Questionnaire assessing upper limb function. Scored on a 7-point scale representing self-perceived difficulty: 1= "totally limited, can't do at all" 7= "not at all limited" Minimum score = 32 Maximum score = 224 (higher score = greater function)

Time frame
Baseline and 6 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Melbourne

Lead sponsor

Institute of Breathing and Sleep

Collaborator

Austin Health

Collaborator

Neuroscience Research Australia

Collaborator

The University of New South Wales

Collaborator

University of Sydney

Collaborator

University of Florida

Collaborator